Research programme: immuno-oncology therapeutics - Bristol-Myers Squibb/Cancer Research Institute/Parker Institute for Cancer Immunotherapy

Drug Profile

Research programme: immuno-oncology therapeutics - Bristol-Myers Squibb/Cancer Research Institute/Parker Institute for Cancer Immunotherapy

Alternative Names: Cancer immunotherapies - Bristol-Myers Squibb/Cancer Research Institute/Parker Institute for Cancer Immunotherapy

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Cancer Research Institute; Parker Institute for Cancer Immunotherapy
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 28 Mar 2017 Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute enter into a clinical research collaboration to develop next-generation precision cancer immunotherapies
  • 28 Mar 2017 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top